Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 931-940

  Van Den Hof, Susan ^a   Berbers, Guy A M ^a   De Melker, Hester E ^a   Conyn Van Spaendonck, Marina A E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Immunity; Measles; Seroprevalence

Indexed keywords

ANTIBODY; MEASLES ANTIBODY; MEASLES VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; GROUPS BY AGE; HUMAN; IMMUNITY; INFANT; MEASLES; MEASLES VACCINATION; NETHERLANDS; NEWBORN; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEASLES VACCINE; MEASLES VIRUS; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; RELIGION AND MEDICINE; SEROEPIDEMIOLOGIC STUDIES; WORLD HEALTH ORGANIZATION;

EID: 0032753935     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00348-5     Document Type: Article

References (33)

1. Markowitz L.E., Katz S.L. Measles vaccine. Plotkin S.A., Mortimer E.A. Jr. Vaccines. 2nd ed. 1994;229-276 WB Saunders, Philadelphia.
2. Black F.L. Measles. Evans A.S. Viral infections of humans: epidemiology and control. 3rd ed. 1989;451-465 Plenum Medical Book Company, New York/London.
3. Cutts F.T., Markowitz L.E. Successes and failures in measles control. J. Infect. Dis. 107:(Suppl. 1):1994;S32-S41.
4. van der Zwan C.W., Plantinga A.D., Rümke H.C., Conyn-van Spaendonck M.A.E. Mazelen in Nederland; epidemiologie en de invloed van vaccinatie. Ned. Tijdschr. Geneeskd. 138:1994;2390-2395.
5. Kacica M.A., Venezia R.A., Miller J., Hughes P.A., Lepow M.L. Measles antibodies in women and infants in the vaccine era. J. Med. Virol. 45:1995;227-229.
6. Christenson B., Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 12:1994;129-133.
7. Brugha R., Ramsay M., Forsey T., Brown D. A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women. Epidemiol. Infect. 117:1996;519-524.
8. Markowitz L.E., Albrecht P., Rhodes P., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Pediatrics. 97:1996;53-58.
9. King J.C., Lichenstein R., Feigelman S., Luna C., Permutt T.J., Patel J. Measles, mumps and rubella antibodies in vaccinated Baltimore children. Am. J. Dis. Child. 147:1993;558-560.
10. Dai Bin, Chen Zhihui, Liu Qichang, Wu Ting, Guo Chengyin, Wang Xingzi, Fang Hanhua, Xiang Yongzhong. Duration of immunity following immunisation with live measles vaccine: 15 years of observation in Zhejiang Province, China. WHO Bulletin OMS. 69:1991;415-423.
11. Poliomyelitis vaccinatie in Nederland. Geubbels E.L.P.E., Conyn-van Spaendonck M.A.E., van Loon A.M. Volksgezondheid Toekomst Verkenning 1997: effecten van preventie. 1997;79-87 Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven.
12. World Health Organization. Strategic plan for the elimination of measles in the European Region. CMDS 01 01 06/10, March 3, 1997. Copenhagen, Denmark: WHO Regional Office for Europe, Copenhagen, Denmark.
13. de Melker H.E., Conyn-van Spaendonck M.A.E. Immunosurveillance and the evaluation of national immunisation programmes: a population-based approach. Epidemiol. Infect. 121:1998;637-643.
14. Inspectie voor de Gezondheidszorg. Vaccinatietoestand Nederland per 1 januari 1996. Rijswijk, The Netherlands, April 1997.
15. Harmsen T., Jongerius M.C., van der Zwan C.W., Plantinga A.D., Kraaijeveld C.A., Berbers G.A.M. Comparison of neutralisation enzyme immuno-assay and enzyme-linked immunosorbent assay for evalutation of the immune status of mumps vaccinated children. J. Clin. Microbiol. 30:1992;2139-2144.
16. Chen R.T., Markowitz L.E., Albrecht P., et al. Measles antibody: re-evaluation of protective titers. J. Infect. Dis. 162:1990;1036-1042.
17. Christenson B., Böttiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus. Biologicals. 18:1990;207-211.
18. Galazka AM. The immunological basis for immunization series. Module 3: Tetanus. WHO/EPI/GEN/93.13. World Health Organization. Geneva, 1993.
19. Foley-Nolan C., Conlon C., Keane E., O'Sullivan M., Ryan F. Survey of immunity to measles in school children in Cork. CDR. 6:1996;R172-R175.
20. Cochran W.G. Sampling techniques. 3rd ed. 1977;John Wiley & Sons, New York.
21. Statistics Netherlands. Vademecum of health statistics of the Netherlands 1997. Ministry of Health, Welfare and Sports, 's-Gravenhage, SDU, 1997.
22. Murphy M.D., Brunell P.A., Lievens A.W., Shebab Z.M. Effect of early immunisation on antibody response to re-immunisation with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics. 77:1984;471-476.
23. Markowitz L.E., Albrecht P., Orenstein W.A., Lett S.M., Pugliese T.J., Farrell D. Persistence of measles antibody after revaccination. J. Infect. Dis. 166:1992;205-208.
24. Huiss S., Damien B., Schneider F., Muller C.P. Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Clin. Exp. Immunol. 109:1997;416-420.
25. Johnson C.E., Kumar M.L., Whitwell J.K., et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at 4 to 6 vs. 11 to 13 years. Pediatr. Infect. Dis. J. 15:1996;687-692.
26. Davidkin I., Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine. 16:1998;2052-2057.
27. Markowitz L.E., Preblud S.R., Fine P.E., Orenstein W.A. Duration of live measles vaccine-induced immunity. Pediatr. Infect. Dis. J. 9:1990;101-110.
28. Panum P.L. Observation made during the epidemic of measles on the Faroe Islands in the year 1846. Med. Classics. 3:1939;839-886.
29. Ward B.J., Boulianne N., Ratnam S., Guiot M.-C., Couillard M., De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172:1995;1591-1595.
30. Krause P.J., Cherry J.D., Carney J.M., Naiditch M.J., O'Connor K. Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am. J. Dis. Child. 135:1980;567-571.
31. Dagan R., Slater P.E., Dubdevani P., Golubev N., Mendelson E. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Pediatr. Infect. Dis. J. 14:1995;965-969.
32. Gustafson T.L., Lievens A.W., Brunell P.A., Moellenberg R.G., Buttery C.M.G., Sehulster L.M. Measles outbreak in a fully immunised secondary-school population. N. Engl. J. Med. 316:1987;771-774.
33. Cohn M.L., Robinson E.D., Faerber M., et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr. Infect. Dis. J. 13:1994;34-38.